





W E hale heard so much data today that an attempt to 
summarize would be futile. It is doubtful that any 
drug used in transplantation has been more extensively 
studied before its first human use than FK 506. One reason 
for this extraordinary care was concern that the agent 
might be toxic and could cause arteritis. gastrointestinal 
complicatwns. diabetes mellitus. or central nervous sys-
tem toxicity. As it has turned out in the clinical trials. the 
drug was not only extraordinarily effective in preventing 
rejection but. in addition. it was relatively free of side 
effects. The drug probably has slight diabetogenic proper-
ties. similar to those of Cy A. However. it can be used with 
such small (or no) doses of steroids that there is a net gain 
in a\oidan..::e of posttransplantation diabetes. By itself. FK 
506 has minor league nephrotoxicity. compared with CyA. 
and probably does not cause hypertension. 
FK 5()t. was used first to reverse rejection in liver 
recipients who had failed to respond to conventional 
therap\. The results greatly exceeded our expectations. 
iiver~ that develop evidence of chronic rejection have not 
been ~ah -igeable with any past therapeutic regimens. 
When liver rejection was controlled with FK 506. it was 
.;uspe..::ted irom the outset that more was being achieved 
than mere:\ switching off the genesis of the disappearing 
hie dUd ,\ ndrome in some of the,e patients. An impres-
'lIe arra\ ,'I subsequent work has sho.,.n that FK 506 can 
d..:tualh c,'ntribute to hepatic regenercttion and repair. This 
:' the fiN ,'ral drug. to my knowledge. which ha, such 
:I~"re:1ieD 
il:~rK dn c\len,il e clinical trial II", initiated. uSing FK 
,'I)n d' pn~Kir~ treatment. fir .. ;t in Iner recipienh. then in 
:~IfrlentD ,'I kidney. heart. lung. hedrt-lung. dnd pancreas 
"liL)gr Jlh .-\lthl)Ugh the follow-up,- are ,,till ,hort with 
t~II>e e\tr.:":epatl( organ,. the rewlt, hale been enCl)Ur· 
,:;:n2. In Kl~K l·\[,enen..:e thdl now eyE~edI (,0 (a,e5. 
\L··c nee . .> te) h: k.lrned .lb,)ut thi: rharm,lcokmell":' of 
FJ.... 'Iif-. r _: cn,)ugh mform,ltlOn h,,' been provided thus 
idr 1'. \·ar.'"ll.lrdmdndn Ithl' i"uel I,) allo\1 it'> erfective 
u,_ In c\:,enmental animals. the e\traordman feat. ae· 
cc'mr':-hc': "\ inlt:'llgatllr' in halfad,'lcn lahoratllric.,. L1r 
tndu_:~IK: . ·~~K!tt accert,tnce after a ,hart coup,e of treat-
ment was highly effective. even when started as late as 4 
days after transplantation. The fact that graft acceptance 
could be induced at such a late time is only the beginning 
of the story. Mechanisms of graft acceptance. which were 
examined by Murase and associates (this issue) are not 
compatible with any of the existing hypotheses of toler-
ance. including clonal deletion. active enhancement. emer-
gence of suppressor cells. or redistribution of lymphocyte 
subsets. 
The results with FK 506 in experimental animals and in 
humans have been so extraordinary that a long list could 
be made of a number of possible achievements which had 
previously been just beyond our grasp. The prospect of 
successfully performing intestinal transplant is supported 
by several papers in this issue. Multivisceral transplanta-
tion. which has never previously been successful in ani-
mals. has now been reported by Murase. A long series of 
autoimmune diseases has also been brought up for consid-
eration for FK 506 therapy. including diseases affecting the 
liver. multiple sclerosis. Crohn's disease. and a variety of 
skin disorders. to provide an incomplete list. 
No one believes that FK 506 will quickly permit suc· 
cessfulxenotransplantation across widely divergent spe-
cies. but any advance which produces such profound 
control of cell·medlated rejection should be applicable to 
resolve at least one aspect of the xenograft reaction. What 
remains to be done is to achieve control of the preformed 
antlbod\ ":L)mpOnent of xenograft rejection. ie. the compo-
nent \\ hl..:h cau,e, instant destruction of the transplant by 
occlu.,lon L)f It., microvasculature. 
We hope that the seminal papers on the development of 
FK 506 \\ hich appear In this monograph will proVide a 
stimulu., fl~r further advances in experimental and clinICal 
tran,plant.ltion. 
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